HUTCHMED (China) Limited (AIM:HCM)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 1.52B -15.2% |
| Revenue (ttm) | 407.54M -13.0% |
| Net Income | 339.48M +1,111.0% |
| EPS | 0.39 +1,200.0% |
| Shares Out | 859.75M |
| PE Ratio | 4.57 |
| Forward PE | 39.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 60,659 |
| Open | 180.00 |
| Previous Close | 174.50 |
| Day's Range | 172.00 - 180.00 |
| 52-Week Range | 172.00 - 292.00 |
| Beta | 0.38 |
| Analysts | Buy |
| Price Target | 350.53 (+101.13%) |
| Earnings Date | Mar 5, 2026 |
About HUTCHMED (China)
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endomet... [Read more]
Financial Performance
In 2025, HUTCHMED (China)'s revenue was $548.51 million, a decrease of -12.96% compared to the previous year's $630.20 million. Earnings were $456.91 million, an increase of 1111.03%.
Financial numbers in USD Financial StatementsNews
HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting
HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of com...
Hutchmed And Innovent Secure NMPA Approval For ELUNATE-TYVYT Combo In Advanced Renal Cell Carcinoma
(RTTNews) - HUTCHMED (HCM) and Innovent Biologics, Inc (HKEX:1801) said the China National Medical Products Administration (NMPA) has approved the combination of ELUNATE (fruquintinib) and TYVYT (sint...
HCM Receives Approval for New Cancer Treatment in China
HCM Receives Approval for New Cancer Treatment in China
Hutchmed, Innovent jointly announce NMPA approval for Elunate/Tyvyt combination
Hutchmed (HCM) and Innovent Biologics jointly announce that the New Drug Application for the combination of Elunate and Tyvyt has been granted approval by the China National Medical Products Administr...
Hutchmed, Innovent Biologics announce China NMPA approval for NDA
Innovent Biologics and Hutchmed (HCM) jointly announce that the new drug application for the combination of Tyvyt and Elunate has been granted approval by the China National Medical Products Administr...
HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study Reduced risk of disease progression or death by 63%, with median PFS of 22.2 mon...
Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma
Reduced risk of disease progression or death by 63%, with median PFS of 22.2 months in the FRUSICA-2 registration study SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics...
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Suites
HiBob recognized as an ISG Vendor of Excellence for its comprehensive Human Capital Management Suite, demonstrating platform growth and market leadership HiBob recognized as an ISG Vendor of Excellenc...
Award-winning HR Software Vendor HiBob Named an ISG 2026 Vendor of Excellence for Human Capital Management (HCM) Platforms
HiBob recognized as an ISG Vendor of Excellence for its innovative HCM Platform, highlighting its ability to unify and streamline global HR operations HiBob recognized as an ISG Vendor of Excellence f...
Chengdu Origen and Vanotech Announce KHN921 Investigational New Drug application clearance by the US FDA for the treatment of hypertrophic cardiomyopathy (HCM) associated with MYBPC3 mutations
Investigational New Drug application for KHN921 received “study may proceed” from the US FDA. KHN921 is a potential "first-in-class" cardiovascular AAV gene therapy being developed for the treatment o...
HCM Receives Priority Review for New Drug Application in China
HCM Receives Priority Review for New Drug Application in China
Hutchmed says NDA for sovleplenib accepted in China
Hutchmed (HCM) announces that the New Drug Application for sovleplenib for the treatment of adult patients with warm antibody autoimmune hemolytic anemia who have had an insufficient response to at…
HUTCHMED (China) Transcript: Deutsche Bank ADR Virtual Investor Conference
Strong sales growth and profitability were highlighted, with robust liquidity supporting R&D and M&A. Key clinical milestones for savolitinib and ATTC platform are expected in late 2025–2026, while new product launches and global expansion remain strategic priorities.
HUTCHMED (China) Slides: Deutsche Bank ADR Virtual Investor Conference
HUTCHMED (China) has posted slides in relation to its latest quarterly earnings report, which was published on April 28, 2026.
HUTCHMED (China) Ltd (HCM) Shares Fall 3.9% -- GF Value Says Still Overvalued
HUTCHMED (China) Ltd (HCM) Shares Fall 3.9% -- GF Value Says Still Overvalued
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several...
HUTCHMED Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registration...
Hutchmed price target lowered to $20 from $21 at BofA
BofA lowered the firm’s price target on Hutchmed (HCM) to $20 from $21 and keeps a Buy rating on the shares following the news that Ipsen (IPSEY) is initiating a…
Hutchmed discontinues all active tazemetostat clinical trials
Hutchmed (HCM) announced an update regarding Tazverik, an oncology therapy licensed from Epizyme, an Ipsen (IPSEY) company, in China. Epizyme is the marketing authorization holder of Tazverik in the C...
HUTCHMED Announces Update on Licensed Oncology Product TAZVERIK® in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces an update regarding T...
Hutchmed price target lowered to $21 from $22 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Hutchmed (HCM) to $21 from $22 and keeps a Buy rating on the shares. The firm says Hutchmed’s FY25 print…
Intended Retirement of Independent Non-executive Director and changes of composition of board committees
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Professor Mok ...
HUTCHMED (China) Earnings Call Transcript: H2 2025
Ex-China FRUZAQLA sales grew 26% to $366M, while China oncology rebounded in H2. Net income reached $457M, aided by a $160M one-time gain. 2026 guidance projects $330M–$450M oncology revenue, with strong pipeline and ATTC clinical progress.
HUTCHMED (China) Annual report: H2 2025
HUTCHMED (China) has published its H2 2025 annual report on March 5, 2026.
HUTCHMED (China) Annual report: H2 2025
HUTCHMED (China) has published its H2 2025 annual report on March 5, 2026.